MedTrace Logo

A Study of PER-001 in Participants With Open-Angle Glaucoma

NCT05822245 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-04-15

No results posted yet for this study

Summary

This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.

Conditions

  • Open-angle Glaucoma

Interventions

DRUG

PER-001 Intravitreal Implant - Low Dose

PER-001 Low Dose Intravitreal Implant

DRUG

PER-001 Intravitreal Implant - High Dose

PER-001 High Dose Intravitreal Implant

DRUG

PER-001 Intravitreal Implant - Sham

PER-001 Intravitreal Sham

Sponsors & Collaborators

  • Perfuse Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Phillip Lai, MD · Perfuse Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-25
Primary Completion
2025-04-04
Completion
2026-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05822245 on ClinicalTrials.gov